RNAi therapeutic strategies for acute respiratory distress syndrome
- 27 July 2019
- journal article
- review article
- Published by Elsevier in Translational Research
- Vol. 214, 30-49
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 251 references indexed in Scilit:
- RNAi Therapeutic Platforms for Lung DiseasesPharmaceuticals, 2013
- Gene Silencing Mediated by siRNA-binding Fusion Proteins Is Attenuated by Double-stranded RNA-binding Domain StructureMolecular Therapy Nucleic Acids, 2012
- A Cell-penetrating Peptide Suppresses Inflammation by Inhibiting NF-κB SignalingMolecular Therapy, 2011
- Gene Therapy for ALI/ARDSCritical Care Clinics, 2011
- Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lungEuropean Journal of Pharmaceutics and Biopharmaceutics, 2011
- Multifunctional Triblock Nanocarrier (PAMAM-PEG-PLL) for the Efficient Intracellular siRNA Delivery and Gene SilencingACS Nano, 2011
- The nuclear signaling of NF-κB: current knowledge, new insights, and future perspectivesCell Research, 2009
- Origins and Mechanisms of miRNAs and siRNAsCell, 2009
- Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissuesAdvanced Drug Delivery Reviews, 2009
- Lung Delivery Studies Using siRNA Conjugated to TAT(48−60) and Penetratin Reveal Peptide Induced Reduction in Gene Expression and Induction of Innate ImmunityBioconjugate Chemistry, 2007